Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317548 | 0.87 | TMPRSS2 (0.44) | TMPRSS2CTSSCTSKBRD4MEN1 | |
| SCHEMBL24917331 | 0.86 | TMPRSS2 (0.44) | TMPRSS2CTSSCTSKMEN1KMT2A | |
| SCHEMBL24791298 | 0.83 | TMPRSS2 (0.53) | TMPRSS2CTSSCTSK | |
| SCHEMBL25909955 | 0.82 | TMPRSS2 (0.40) | TMPRSS2CTSSCTSKMEN1KMT2A | |
| SCHEMBL25917292 | 0.82 | TMPRSS2 (0.44) | TMPRSS2CTSSCTSKBRD4EGFR | |
| SCHEMBL24917355 | 0.82 | TMPRSS2 (0.44) | TMPRSS2CTSSCTSKBRD4EGFR | |
| SCHEMBL25315489 | 0.82 | TMPRSS2 (0.62) | TMPRSS2ATM | |
| SCHEMBL24917215 | 0.81 | TMPRSS2 (0.43) | TMPRSS2CTSSCTSKBRD4 | |
| SCHEMBL24917179 | 0.81 | TMPRSS2 (0.45) | TMPRSS2CTSSCTSKBRD4EGFR | |
| SCHEMBL25909498 | 0.81 | TMPRSS2 (0.42) | TMPRSS2CTSSCTSKBRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885CTSS 1351/4885CTSK 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.